Good times aheadThere seems to be a reason why Theralase didn't show up at ASCO (given where it is in its trial) and didn't put out a press release on the Ph. 1b patients #5 and #6 unbelievabe milestone that have been cancer free for 540 consecutive days with only 1 dose (and so, no maintenance). They simply mentioned it in the MD&As.
I think it has to do with them not wanting to irritate some egos and wait for more Ph. 2 data before making an official splash, given the giant leap this treatment will allow.
As per the recent AUA2022 articles I posted this morning, you can see how our treatment would be amazingly disruptive. I assume that maintenance schedules are bringing a lot of revenues to urologists. This could be an issue for some of them. We'll have to see how our treatment is received, just on that simple factor. Money is something that sometimes become important to some.